<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04184661</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0725</org_study_id>
    <secondary_id>2019-A02914-53</secondary_id>
    <nct_id>NCT04184661</nct_id>
  </id_info>
  <brief_title>Burosumab and 1-25 (OH) Vitamin D on Human Osteoclasts</brief_title>
  <acronym>HYPO-CLASTE</acronym>
  <official_title>Effect of Burosumab and 1-25 (OH) Vitamin D on Human Osteoclasts From Patients With Hypophosphatemic Rickets (HR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fibroblast growth factor 23 (FGF23) is the cornerstone of phosphate / calcium / vitamin D&#xD;
      metabolism: it is synthesized mainly by osteocytes and acts as a Phosphating agent, inhibitor&#xD;
      of dihydroxyvitamin D, and inhibitor of synthesis and secretion of Parathyroid hormone (PTH)&#xD;
      in most tissues.&#xD;
&#xD;
      The specific role of FGF23 on bone has yet to be demonstrated. In some diseases such as&#xD;
      hypophosphatemic rickets (HR), the direct role of FGF23 on bone has not yet been studied to&#xD;
      our knowledge, whereas these genetic hypophosphatemias are secondary to overexpression of&#xD;
      FGF23, whether an activating mutation of FGF23 or inhibitory mutations of its inhibitors&#xD;
      (Dentin matrix acidic phosphoprotein 1 (DMP1) and Phosphate-regulating neutral endopeptidase,&#xD;
      X-linked (PHEX)). However, patients with X-linked hypophosphatemic rickets (XLH) have higher&#xD;
      circulating FGF23 levels than healthy controls and these levels are higher in treated&#xD;
      patients.&#xD;
&#xD;
      Management of XLH consists primarily of correcting the native vitamin D defect by prescribing&#xD;
      active vitamin D analogs as well as phosphate supplementation to improve bone mineralization&#xD;
      and decrease dental complications, growth, and bone deformities. Recently, a new therapeutic&#xD;
      option has been developed for XLH, burosumab, a human monoclonal antibody that binds and&#xD;
      inhibits FGF23 activity. The use of burosumab is currently authorized in France in some&#xD;
      pediatric patients with severe forms of XLH.&#xD;
&#xD;
      Independently of the indirect bone effects of phosphate correction and vitamin D levels, the&#xD;
      direct role of burosumab on bone cells has never been studied. The objective of this project&#xD;
      is to study the osteoclastic biology of patients with HR compared to control patients, and to&#xD;
      evaluate the direct impact of the treatments used in this pathology on human osteoclasts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Anticipated">January 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 20, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of osteoclastic cells obtained after at the end of differentiation</measure>
    <time_frame>1 day</time_frame>
    <description>The analysis of osteoclastic differentiation will be obtained from the bone cells from patients with burosumab and/or 1-25 (OH) vitamin D</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hypophosphatemic Rickets</condition>
  <arm_group>
    <arm_group_label>hypophosphatemic rickets patients</arm_group_label>
    <description>30 hypophosphatemic rickets patients older than 2 years will be included in this study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controls patients</arm_group_label>
    <description>10 controls patients from pediatric nephrology unit without hypophosphatemic rickets, older than 2 years will be included in this study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>25 mL blood sample will be collected on citrate tubes for osteoclastic analysis.</description>
    <arm_group_label>controls patients</arm_group_label>
    <arm_group_label>hypophosphatemic rickets patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      25 mL blood sample will be collected on citrate tubes for osteoclastic analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with hypophosphatemic rickets and controls patients without hypophosphatemic&#xD;
        rickets&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        hypophosphatemic rickets patients:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  children from 2 yars-old to 18 years old and adults&#xD;
&#xD;
          -  patients with HR followed in the center of calcium and phosphorus metabolism rare&#xD;
             diseases in Lyon-&#xD;
&#xD;
          -  Patients and parent / holder of parental authority who have been informed of the study&#xD;
             and do not object to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient being treated with oral corticosteroid or having received more than 3 months&#xD;
             of corticosteroid treatment before surgery.&#xD;
&#xD;
          -  Patients under tutorship or curatorship&#xD;
&#xD;
          -  Pregnant and / or breastfeeding woman&#xD;
&#xD;
          -  Patient deprived of liberty&#xD;
&#xD;
        Controls patients:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  children from 2 years-old to 18 years old and adults&#xD;
&#xD;
          -  patients with normal renal function (Schwartz glomerular filtration rate (GFR) &gt;90&#xD;
             ml/min/1.73m²)&#xD;
&#xD;
          -  Patients and parent / holder of parental authority who have been informed of the study&#xD;
             and do not object to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient being treated with oral corticosteroid or having received more than 3 months&#xD;
             of corticosteroid treatment before surgery.&#xD;
&#xD;
          -  Patients under tutorship or curatorship&#xD;
&#xD;
          -  Pregnant and / or breastfeeding woman&#xD;
&#xD;
          -  Patient deprived of liberty&#xD;
&#xD;
          -  Patient treated with immunosuppressive drugs&#xD;
&#xD;
          -  Patient with inflammatory disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Justine BACCHETTA, PU,PH</last_name>
    <phone>04 27 85 61 30</phone>
    <phone_ext>+33</phone_ext>
    <email>justine.bacchetta@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sacha FLAMMIER, project Manager</last_name>
    <phone>0472681349</phone>
    <phone_ext>+33</phone_ext>
    <email>sacha.flammier@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Femme mère enfant</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justine BACCHETTA, PU,PH</last_name>
      <phone>04 27 85 61 30</phone>
      <phone_ext>+33</phone_ext>
      <email>justine.bacchetta@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sacha FLAMMIER, project Manager</last_name>
      <phone>0472681349</phone>
      <phone_ext>+33</phone_ext>
      <email>sacha.flammier@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Justine BACCHETTA, PU,PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LEMOINE Sandrine, MD,PhD</last_name>
      <email>sandrine.lemoine@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>LEMOINE Sandrine, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre Paris Saclay</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>LINGLART Agnès, PU,PH</last_name>
      <email>agnes.linglart@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>LINGLART Agnès, PU,PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 28, 2019</study_first_submitted>
  <study_first_submitted_qc>November 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2019</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rickets</mesh_term>
    <mesh_term>Rickets, Hypophosphatemic</mesh_term>
    <mesh_term>Familial Hypophosphatemic Rickets</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

